Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 66
- Registration Number
- NCT03416244
- Locations
- 🇩🇪
Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT03409198
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇳🇴Soerlandet Hospital HF Kristiansand, Kristiansand, Norway
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 97
- Registration Number
- NCT03409848
- Locations
- 🇩🇪
Klinikum Wolfsburg - Med. II, Wolfsburg, Germany
🇩🇪Stauferklinikum Schwäbisch Gmünd - Innere Med., Mutlangen, Germany
🇩🇪Klinikum rechts der Isar der TU München - Innere Med. III, München, Germany
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 140
- Registration Number
- NCT03406247
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2023-03-30
- Target Recruit Count
- 14
- Registration Number
- NCT03406715
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT03391869
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT03388632
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT03387761
- Locations
- 🇳🇱
Radboud UMC, Nijmegen, Netherlands
🇳🇱UMC Utrecht, Utrecht, Netherlands
🇳🇱Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 68
- Registration Number
- NCT03377023
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 325
- Registration Number
- NCT03377361
- Locations
- 🇺🇸
Local Institution - 0111, Miami, Florida, United States
🇨🇱Local Institution - 0118, Santiago, Región Metropolitana De Santiago, Chile
🇺🇸Local Institution - 0002, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.